| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633015 | JANSSEN PHARMS | Beads having a core coated with an antifungal and a polymer |
May, 2014
(9 years ago) | |
| US5707975 | JANSSEN PHARMS | Oral formulations on an antifungal |
Jan, 2015
(9 years ago) | |
| US6407079 | JANSSEN PHARMS | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
Jun, 2019
(4 years ago) | |
Sporanox is owned by Janssen Pharms.
Sporanox contains Itraconazole.
Sporanox has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Sporanox are:
- US5633015
- US5707975
- US6407079
Sporanox was authorised for market use on 11 September, 1992.
Sporanox is available in capsule;oral, injectable;injection dosage forms.
The generics of Sporanox are possible to be released after 18 June, 2019.
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 September, 1992
Treatment: NA
Dosage: CAPSULE;ORAL; INJECTABLE;INJECTION
How can I launch a generic of SPORANOX before it's drug patent expiration?
More Information on Dosage
SPORANOX family patents
